Premium
Enhanced osteogenic differentiation of human mesenchymal stem cells by direct delivery of Cbfβ protein
Author(s) -
Lee Jaeyoung,
Cha Hyeonjin,
Park Tai Hyun,
Park Ju Hyun
Publication year - 2020
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.27453
Subject(s) - runx2 , mesenchymal stem cell , adipogenesis , microbiology and biotechnology , osteoblast , downregulation and upregulation , transcription factor , adipocyte , chemistry , intracellular , biology , gene , biochemistry , adipose tissue , in vitro
Core binding factor β (Cbfβ) is a non‐DNA binding cofactor of Runx2 that potentiates DNA binding. Previously, it has been reported that Cbfβ plays an essential role in osteogenic differentiation and skeletal development by inhibition adipogenesis. Here, we delivered the recombinant Cbfβ protein into human mesenchymal stem cells (MSCs) and triggered osteogenic lineage commitment. The efficient delivery of Cbfβ was achieved by fusing 30Kc19 protein, which is a cell‐penetrating protein derived from the silkworm. After the production of the recombinant Cbfβ‐30Kc19 protein in the Escherichia coli expression system, and confirmation of its intracellular delivery, MSCs were treated with the Cbfβ‐30Kc19 once or twice up to 300 µg/ml. By investigating the upregulation of osteoblast‐specific genes and phenotypical changes, such as calcium mineralization, we demonstrated that Cbfβ‐30Kc19 efficiently induced osteogenic differentiation in MSCs. At the same time, Cbfβ‐30Kc19 suppressed adipocyte formation and downregulated the expression of adipocyte‐specific genes. Our results demonstrate that the intracellularly delivered Cbfβ‐30Kc19 enhances osteogenesis in MSCs, whereas it suppresses adipogenesis by altering the transcriptional regulatory network involved in osteoblast‐adipocyte lineage commitment. Cbfβ‐30Kc19 holds great potential for the treatment of bone‐related diseases, such as osteoporosis, by allowing transcriptional regulation in MSCs, and overcoming the limitations of current therapies.